Insider Selling: Glaukos Corporation (GKOS) Director Sells $22,471,146.00 in Stock
Glaukos Corporation (NYSE:GKOS) Director Orbimed Advisors Llc sold 580,200 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $38.73, for a total transaction of $22,471,146.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Orbimed Advisors Llc also recently made the following trade(s):
- On Thursday, August 17th, Orbimed Advisors Llc sold 325,000 shares of Glaukos Corporation stock. The stock was sold at an average price of $37.93, for a total transaction of $12,327,250.00.
Glaukos Corporation (GKOS) opened at 41.45 on Friday. The firm’s market capitalization is $1.43 billion. Glaukos Corporation has a 12 month low of $28.72 and a 12 month high of $52.49. The stock’s 50 day moving average is $38.45 and its 200-day moving average is $42.55.
A number of large investors have recently bought and sold shares of the stock. Janus Henderson Group PLC acquired a new stake in Glaukos Corporation during the 2nd quarter worth approximately $129,356,000. Capital World Investors boosted its position in Glaukos Corporation by 17.1% during the 2nd quarter. Capital World Investors now owns 2,740,000 shares of the medical instruments supplier’s stock worth $113,628,000 after buying an additional 400,000 shares during the period. William Blair Investment Management LLC boosted its position in Glaukos Corporation by 4.9% during the 2nd quarter. William Blair Investment Management LLC now owns 2,164,764 shares of the medical instruments supplier’s stock worth $89,773,000 after buying an additional 100,320 shares during the period. Janus Capital Management LLC boosted its position in Glaukos Corporation by 88.5% during the 1st quarter. Janus Capital Management LLC now owns 1,765,069 shares of the medical instruments supplier’s stock worth $90,545,000 after buying an additional 828,567 shares during the period. Finally, Vanguard Group Inc. boosted its position in Glaukos Corporation by 3.4% during the 2nd quarter. Vanguard Group Inc. now owns 1,668,345 shares of the medical instruments supplier’s stock worth $69,187,000 after buying an additional 55,507 shares during the period.
A number of brokerages have recently issued reports on GKOS. Zacks Investment Research upgraded shares of Glaukos Corporation from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a research report on Friday, August 4th. BidaskClub upgraded shares of Glaukos Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, August 16th. BMO Capital Markets reiterated a “buy” rating and set a $54.00 target price on shares of Glaukos Corporation in a research report on Friday, September 1st. Finally, Roth Capital reduced their target price on shares of Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating on the stock in a research report on Thursday, August 3rd. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $52.33.
About Glaukos Corporation
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Stock Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related stocks with our FREE daily email newsletter.